Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

An Injectable Hf-Alendronate Supramolecular Condensate Enables Radioimmunotherapy for Osteosarcoma via COX-2/PGE2 Inhibition and Systemic Immune Activation

ABSTRACT: Radiotherapy (RT) is commonly employed as an adjuvant treatment after surgical resection of osteosarcoma. However, its therapeutic effectiveness is frequently constrained by inadequate radiosensitization and an immunosuppressive tumor microenvironment, which hinders systemic antitumor immune responses and facilitates tumor recurrence and metastasis. In this study, We designed an injectable supermolecular complex of alendronate (Hf-ALN) containing the COX-2 inhibitor celecoxib (CXB), and combined it with radiotherapy to treat osteosarcoma in Balb/c mice. Subsequently, transcriptome analysis was conducted.This injectable radiological immunomodulatory aggregate represents a promising approach that integrates local radiosensitization with immune microenvironment reprogramming to enhance the efficacy of postoperative radiotherapy for osteosarcoma.

ORGANISM(S): Mus musculus

PROVIDER: GSE325820 | GEO | 2026/09/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

An Injectable Hf-Alendronate Supramolecular Condensate Enables Radioimmunotherapy for Osteosarcoma via COX-2/PGE2 Inhibition and Systemic Immune Activation

Project description:An Injectable Hf-Alendronate Supramolecular Condensate Enables Radioimmunotherapy for Osteosarcoma via COX-2/PGE2 Inhibition and Systemic Immune Activation

| PRJNA1442013 | ENA

Injectable anti-inflammatory supramolecular nanofiber hydrogel to promote ranibizumab therapy in age-related macular degeneration treatment

Project description:The exact pathogenesis of age-related macular degeneration (AMD) leading to visual impairment and severe vision loss is still unclear, and the currently available treatments are often unsatisfactory. Previous studies have demonstrated both oxidative stress-induced damage to the retinal pigment epithelium (RPE) and inflammation are involved in AMD. Although anti-vascular endothelial growth factor (VEGF) therapy can impair the growth of new blood vessels, serious side effects were found with repeated monthly intravitreal injections. Here, an injectable hydrogel based on an anti-inflammatory betamethasone phosphate (BetP) drug (BetP-Gel) was designed to enable long-term efficient release of ranibizumab (RZB) to attenuate choroidal neovascularization (CNV), reduce vascular leakage and inhibit vascular proliferation in the retina, which significantly increased the effective treatment time of ranibizumab compared with that in clinical practice. In particular, experimental data with in vitro and in vivo models revealed that BetP-Gel itself had a strong ability to scavenge intracellular reactive oxygen species (ROS) and reduce tumour necrosis factor-α (TNF-α) as well as interleukin (IL-1β, IL-6, IL-8, and IL-18) inflammatory cytokines, inhibiting ROS- and inflammation-induced retinal damage. Altogether, the carrier-free system (RZB@BetP-Gel) could serve as a novel antioxidant, anti-inflammatory and anti-neovascularization agent for the treatment of AMD.

2024-01-28 | GSE165702 | GEO

PTH treatment prior to cyclic joint loading improves cartilage health and attenuates load-induced osteoarthritis development in mice

Project description:Osteoarthritis (OA) treatment is limited by the lack of effective non-surgical interventions to slow disease progression. Here, we examined the contributions of the subchondral bone properties to OA development. We used parathyroid hormone (PTH) to modulate bone mass prior to OA initiation and alendronate (ALN) to inhibit bone remodeling during OA progression. We examined the spatiotemporal progression of joint damage by combining histopathological and transcriptomic analyses across joint tissues. The additive effect of PTH pretreatment prior to OA initiation and ALN treatment during OA progression most effectively attenuated load-induced OA pathology. Individually, PTH directly improved cartilage health and slowed the development of cartilage damage, whereas ALN primarily attenuated subchondral bone changes associated with OA progression. Joint damage reflected early transcriptomic changes. With both treatments the structural changes were associated with early modulation of immunoregulation and -response pathways that may contribute to disease mechanisms. Overall, our results demonstrate the potential of subchondral bone-modifying therapies to slow the progression of OA.

2024-01-31 | GSE253303 | GEO

Alendronate and Osteonecrosis of the Jaw

Project description:Objectives: Osteonecrosis of the jaw (ONJ), a necrotic bone disease unique to the craniofacial region, is often observed among cancer patients treated with bisphosphonate (BP)-based chemotherapy and becomes a costly and debilitating source of pain and reduced quality of life. Elucidation of clinicopathological mechanism and biomarkers of ONJ that can indicate probable disease course would allow for better assessment of treatment strategies for individual patients. To address our overall goal of identifying novel diagnostic and prognostic strategies for ONJ, this study specifically aims to understand the alendronate (ALN) treatment-induced perturbation of bone proteome and microenvironmental pathophysiology of ONJ using targeted molecular analyses and computational approaches based on an in vitro cell culture system. This study also focuses on identifying proteome perturbation and potential molecular biomarkers during ONJ development. Methods: To understand the molecular mechanisms underlying ONJ, an unbiased and global proteomics approach combined with big data analysis using bioinformatics was applied. Biochemical and functional analyses were followed to tease out the mechanisms regulated by ALN treatment. Results: The current findings from our global proteomics study and biochemical analyses suggested that the RIPK3/Wnt/GSK3/β-catenin signaling pathway is significantly perturbed upon alendronate treatment, resulting in abnormal angiogenesis/inflammation/bone anabolism/remodeling/bone mineralization in the in vitro cell culture system. Conclusion: This investigation on potential key signaling mechanisms underlying ONJ will provide a rational basis for suppressing BP-induced ONJ and novel therapeutic strategies against ONJ.

2021-09-10 | PXD024585 | Pride

Enhanced Osteogenesis of Mesenchymal Stem Cells Encapsulated in Injectable Microporous Hydrogel

Project description:Delivery of therapeutic stem cells to treat bone tissue damage is a promising strategy that faces many hurdles to clinical translation. Among them is the design of a delivery vehicle which promotes desired cell behavior for new bone formation. In this work, we describe the use of an injectable microporous hydrogel, made of crosslinked gelatin microgels, for the encapsulation and delivery of human mesenchymal stem cells (MSCs) and compared it to a traditional nonporous injectable hydrogel. MSCs encapsulated in the microporous hydrogel showed rapid cell spreading with direct cell-cell connections whereas the MSCs in the nonporous hydrogel were entrapped by the surrounding polymer mesh and isolated from each other. Microporous hydrogel induced more robust osteogenic differentiation of MSCs and calcium mineral deposition than the nonporous hydrogel confirmed by alkaline phosphatase (ALP) assay and calcium assay. RNA-seq confirmed the upregulation of the genes and pathways that are associated with cell spreading and cell-cell connections, as well as the osteogenesis in the microporous hydrogel. These results demonstrate that the microgel-based injectable hydrogels can be useful tools for therapeutic cell delivery for bone tissue repair.

2024-04-15 | GSE263939 | GEO

Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors

Project description:This is a Phase 1 open-label study of SN2310 Injectable Emulsion in patients with advanced solid malignancies. The study is designed to determine the maximum tolerated dose and dose-limiting toxicity of SN2310 Injectable Emulsion, and to characterize the pharmacokinetics of SN2310 and SN-38 following intravenous administration of SN2310 Injectable Emulsion. Additionally, evaluation of side effects as a function of dose, and observation of any anti-tumor effects of SN2310 Injectable Emulsion will be made.

| 2033356 | ecrin-mdr-crc

Injectable anti-inflammatory supramolecular nanofiber hydrogel to promote ranibizumab therapy in age-related macular degeneration treatment

Project description:Injectable anti-inflammatory supramolecular nanofiber hydrogel to promote ranibizumab therapy in age-related macular degeneration treatment

| PRJNA695504 | ENA

NanoStrong miRNA from DU145 CF and HF cells

Project description:NanoString duplicate runs were created for CF- and HF-resistant cells, and for matched parental duplicate samples corresponding to each radioresistant cell type. Prostate cancer is the second most common cause of cancer death in men, and radiotherapy is a standard curative therapy for localized disease. Unfortunately, aggressive radioresistant relapses can arise, and the molecular underpinnings of radioresistance are unknown. Modern clinical radiotherapy is evolving to deliver higher doses of radiation in fewer fractions (hypofractionation). We therefore analyzed genomic, transcriptomic and proteomic data to characterize the determinants of prostate cancer radioresistance in cells treated with both conventionally fractionated and hypofractionated radiotherapy. Independent of fractionation schedule, resistance to radiotherapy involved massive genomic instability and abrogation of DNA mismatch repair. Specific prostate cancer driver genes were modulated at the RNA and protein levels, with distinct protein subcellular responses to radiotherapy. Conventional fractionation led to a far more aggressive biomolecular response than hypofractionation. Testing pre-clinical candidates identified in cell lines, we revealed POLQ as a radiosensitizer. POLQ-modulated radioresistance in model systems and was predictive of it in large patient cohorts. Pharmacologic and genetic inhibition of POLQ re-sensitized radioresistant cells, creating signatures seen in primary patient cohorts. The molecular response to radiation is highly multi-modal, and sheds light on prostate cancer lethality.

2024-08-24 | GSE241078 | GEO

Tailoring an Intravenously Injectable Oncolytic Virus for Augmenting Radiotherapy

Project description:Oncolytic viruses (OVs) combined with radiotherapy (RT) have shown promise in clinical trials but remain limited by unsatisfactory efficacy. Key challenges include poor intravenous delivery, insufficient RT-induced DNA damage, and suboptimal anti-tumor immune responses. Herein, we developed a novel oncolytic adenovirus (AD) formulation, RadioOnco (AD@PSSP), which incorporates multifunctional polyethyleneimine (PEI)-selenium-PEG (PSSP) to enhance intravenous delivery, viral infectivity, immune response and the efficacy of radiotherapy. The PEGylation shields the virus from rapid clearance, while the ROS-responsive Se-Se bond enables targeted delivery at tumor sites following RT. The exposed PEI enhanced infectivity of AD through electrostatic interactions, consequently augmenting DNA damage after RT via inhibiting the expression of DNA-repair proteins, such as CHEK1 and CDK1. Furthermore, AD-PEI can capture and deliver the RT-induced tumor-released antigens to lymph nodes, thereby activating robust anti-tumor immune responses. Our data from diverse animal models have shown that RadioOnco exhibits unique characteristics, including reversing RT resistance, ability for distant killing, and long-term memory retention, all of which are crucial for addressing metastasis and recurrence in clinical RT. In summary, we have devised an intravenously injectable OVs with synergistic effects in conjunction with RT, achieved through the surface modification of a multifunctional material.

2025-02-02 | PXD060493 |

Project description:Tailoring an Intravenously Injectable Oncolytic Virus for Augmenting Radiotherapy

| PRJNA1215939 | ENA